Epidemiology and burden of progressive familial intrahepatic cholestasis: a systematic review
Open Access
- 3 June 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Orphanet Journal of Rare Diseases
- Vol. 16 (1), 1-14
- https://doi.org/10.1186/s13023-021-01884-4
Abstract
Background: Progressive familial intrahepatic cholestasis is a rare, heterogeneous group of liver disorders of autosomal recessive inheritance, characterised by an early onset of cholestasis with pruritus and malabsorption, which rapidly progresses, eventually culminating in liver failure. For children and their parents, PFIC is an extremely distressing disease. Significant pruritus can lead to severe cutaneous mutilation and may affect many activities of daily living through loss of sleep, irritability, poor attention, and impaired school performance. Methods: Databases including MEDLINE and Embase were searched for publications on PFIC prevalence, incidence or natural history, and the economic burden or health-related quality of life of patients with PFIC. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Results: Three systematic reviews and twenty-two studies were eligible for inclusion for the epidemiology of PFIC including a total of 2603 patients. Study periods ranged from 3 to 33 years. Local population prevalence of PFIC was reported in three studies, ranging from 9.0 to 12.0% of children admitted with cholestasis, acute liver failure, or splenomegaly. The most detailed data come from the NAPPED study where native liver survival of >15 years is predicted in PFIC2 patients with a serum bile acid concentration below 102 µmol/L following bile diversion surgery. Burden of disease was mainly reported through health-related quality of life (HRQL), rates of surgery and survival. Rates of biliary diversion and liver transplant varied widely depending on study period, sample size and PFIC type, with many patients have multiple surgeries and progressing to liver transplant. This renders data unsuitable for comparison. Conclusion: Using robust and transparent methods, this systematic review summarises our current knowledge of PFIC. The epidemiological overview is highly mixed and dependent on presentation and PFIC subtype. Only two studies reported HRQL and mortality results were variable across different subtypes. Lack of data and extensive heterogeneity severely limit understanding across this disease area, particularly variation around and within subtypes.Keywords
Funding Information
- Albireo Pharma, Inc
This publication has 49 references indexed in Scilit:
- Differences in presentation and progression between severe FIC1 and BSEP deficienciesJournal of Hepatology, 2010
- ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): Phenotypic differences between PFIC1 and PFIC2 and natural historyJournal of Hepatology, 2010
- Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantationLiver Transplantation, 2009
- Nontransplant surgical interventions in progressive familial intrahepatic cholestasisJournal of Pediatric Surgery, 2009
- Liver Transplantation in Children With Progressive Familial Intrahepatic CholestasisTransplantation, 2007
- Liver transplantation for progressive familial intrahepatic cholestasis: Clinical and histopathological findings, outcome and impact on growthPediatric Transplantation, 2007
- Ursodeoxycholic acid treatment in children with Byler diseasePediatrics International, 1999
- Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasisJournal of Hepatology, 1997
- Selective surgical management of progressive familial intrahepatic cholestasis (Byler's disease)Journal of Pediatric Surgery, 1995
- Cholestatic jaundice in infancy. The importance of familial and genetic factors in aetiology and prognosis.Archives of Disease in Childhood, 1981